Crinetics Pharmaceuticals (CRNX) Q2 2026 earnings — TrendMatrix coverage
BEAT · SMALLER LOSS+3.7% vs estimateEPS -$1.14 vs -$1.18 est
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
Key numbers
- Adjusted EPS
- -$1.14
- Estimate
- -$1.18
- Surprise
- +3.7%
- Revenue (period 2026-06-30)
- $25.1M
Revenue source: xbrl.
Report record · Q2 2026
How the report landed
Crinetics Pharmaceuticals (CRNX) reported a narrower loss than forecast — adjusted EPS of -$1.14 against the -$1.18 estimate (a 3.7% beat on a still-unprofitable quarter).